Allergan Plans to Expand in New Jersey
The EDA offered Allergan tax credits in order to encourage the company to remain in the state.
On August 9, 2016, the Board of the New Jersey Economic Development Authority (EDA) approved Grow New Jersey (Grow NJ) tax credits in order to encourage Allergan to remain in NJ. The EDA is also encouraging Allergan to combine its four existing company locations into a 431,495-square-foot facility in Madison, NJ.
The Board approved Allergan for Grow NJ tax credits of up to $58.2 million over 10 years based on the expected creation of 300 new, high-paying jobs, the retention of more than 1000 jobs at risk of leaving the state for Pennsylvania, and private investment of more than $103 million. The project is expected to result in a net benefit to the state of more than $384 million over 20 years.
Allergan subsidiaries Watson Pharmaceuticals, in Parsippany, and Forest Laboratories, in Jersey City, have existing projects approved under the Business Employment Incentive Program. Those grants will be required to be withdrawn in order for Allergan to qualify for the Madison Grow NJ project, forfeiting more than $15.2 million in future payments.
Source: NJ EDA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
